Choloroquine reduces formation of bone resorbing cells in murine osteoporosis

Bone homeostasis requires precise balance between deposition of new bone by osteoblasts and resorption of old bone by osteoclasts. Bone diseases, including osteoporosis and rheumatoid arthritis, are the result of increased osteoclast activity and formation, which allows bone resorption to outpace deposition.

In this issue of the Journal of Clinical Investigation, Brendan Boyce and colleagues at the University of Rochester evaluated the role of TNF receptor–associated receptor 3 (TRAF3) in promoting osteoclast formation. Mice lacking TRAF3 in osteoclast precursor cells had mild osteoporosis that was associated with increased osteoclast formation.

The authors found that chloroquine treatment increased TRAF3 in osteoclast precursor cells and limited osteoclast generation. Furthermore, treatment of mouse models of osteoporosis with chloroquine inhibited osteoclast formation.

These studies implicate that therapies aimed at increasing TRAF3 in osteoclast precursor cells may limit for those with bone diseases.

Explore further

New target identified for preventing bone destruction in diseases such as arthritis and cancer

More information: Chloroquine reduces osteoclastogenesis in murine osteoporosis by preventing TRAF3 degradation, J Clin Invest. DOI: 10.1172/JCI66947
Citation: Choloroquine reduces formation of bone resorbing cells in murine osteoporosis (2013, December 9) retrieved 24 August 2019 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more